医学
白细胞减少症
依托泊苷
内科学
临床研究阶段
放射治疗
临床终点
胃肠病学
不利影响
前瞻性队列研究
存活率
肿瘤科
化疗
临床试验
作者
Xing-Wen Fan,Yu Yang,Hong-Bing Wang,Yin Xu,Mei Kang,Li-Yi Xie,Ling Li,Wentao Fang,Kuaile Zhao,Haiquan Chen,Jia-Qing Xiang,Yee Ung,Chong Shun Wong,Guo-Liang Jiang,Kailiang Wu
标识
DOI:10.1016/j.ijrobp.2019.12.045
摘要
PURPOSE: This prospective phase 2 study evaluated the efficacy and safety of intensity modulated radiation therapy plus etoposide/cisplatin (EP) for patients with unresectable thymic epithelial tumors (TETs). METHODS AND MATERIALS: cisplatin on days 1-3 and days 29-31) were administered concurrently with radiation therapy, followed by 2 cycles after radiation therapy. The primary endpoint was the objective response rate. The secondary endpoints were the progression-free survival rate, overall survival rate, and incidence of adverse events. RESULTS: Fifty-six patients were enrolled between June 2011 and May 2018. Twenty-two and 34 patients had thymomas and thymic carcinomas, respectively. The median age was 52 (range, 21-76) years, and 30 patients (53.6%) were men. Eight patients (14.3%) had stage III tumors, 6 (10.7%) had stage IVA tumors, and 42 (75.0%) had stage IVB tumors. The objective response rate was 85.7% (95% confidence interval, 76.3%-95.2%). With a median follow-up of 46 (range, 7-101) months, the 1-, 2-, and 5-year progression-free survival rates were 66.1%, 48.0%, and 29.5%, and the 1-, 2-, and 5-year overall survival rates were 91.0%, 76.2%, and 56.2%, respectively. The most common grade 3 to 4 adverse event was leukopenia (42.9%). Pulmonary fibrosis was also observed (5.3%). CONCLUSIONS: Because intensity modulated radiation therapy with EP is effective and safe for limited advanced unresectable TETs, it could be a suitable treatment option for such patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI